821 results on '"Kameda, Hideto"'
Search Results
52. OA34 Post-hoc analysis of spinal MRI SPARCC inflammation scores in patients with radiographic axial spondyloarthritis treated with ixekizumab: results from the COAST-V study at week 16
53. P275 Association of the improvement of synovitis and enthesitis with quality of life/patient reported outcomes in patients with psoriatic arthritis treated with ixekizumab
54. 3. Early Diagnosis of Collagen Diseases
55. Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial
56. Improvement of Renal Function with Selective Thromboxane A2 Synthetase Inhibitor, DP-1904 in Lupus Nephritis
57. Haemoglobin changes and disease activity in Japanese patients with rheumatoid arthritis treated with sarilumab
58. A nationwide questionnaire survey on the prevalence of ankylosing spondylitis and non-radiographic axial spondyloarthritis in Japan
59. Good response to methotrexate is associated with a decrease in the gene expression of ABCG2, a drug transporter, in patients with rheumatoid arthritis
60. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
61. Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression
62. Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis
63. Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials
64. Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD)
65. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology
66. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs
67. Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis
68. Additional file 3 of Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)
69. Additional file 2 of Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)
70. Additional file 1 of Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT
71. Association of the improvement of Synovitis and Enthesitis with quality of life/patient reported outcomes in patients with PsA treated with Ixekizumab
72. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)
73. Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept
74. Successful treatment of adult-onset Still’s disease with tocilizumab monotherapy: two case reports and literature review
75. Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus
76. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)
77. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial
78. Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis
79. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy
80. Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction
81. Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis
82. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J)
83. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)
84. Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis.
85. P190 Secukinumab improves back pain, morning stiffness, fatigue and physical function in tumour necrosis factor inhibitor-naive patients with non-radiographic axial spondyloarthritis: results from a randomised controlled Phase 3 study
86. Finger Joint Cartilage Evaluated by Semiquantitative Ultrasound Score in Patients With Rheumatoid Arthritis
87. Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis
88. Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis
89. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM)
90. Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab
91. Efficacy and safety of bucillamine, a d-penicillamine analogue, in patients with active rheumatoid arthritis
92. Regulation of T cell differentiation by the AP-1 transcription factor JunB
93. Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients
94. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
95. A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study
96. Limit Dextrinosis
97. Lipoproteinosis
98. Lisch Epithelial Corneal Dystrophy
99. Livedo Telangiectatica
100. Lactase Nonpersistence
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.